Martin, J., Gomez, J.C., Garcia-Bernardo, E., Cuesta, M., Alvarez, E. and Gurpegui, M. (Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia Spain) (1997) Olanzapine in treatment-refractory schizophrenia: Results of an open label study. Journal of Clinical Psychiatry, 58, 479-483. doi:10.4088/JCP.v58n1103

has been cited by the following article:

• TITLE: Very-high-dose olanzapine for treatment-resistant schizophrenia

  AUTHORS: Jean-Marie Batail, Sophie Bleher, Clément Lozachmeur, Gabriel Robert, Bruno Millet, Dominique Drapier

  KEYWORDS: Schizophrenia; Treatment Resistance; High-Dose Olanzapine; Treatment Tolerance

  JOURNAL NAME: Open Journal of Psychiatry, Vol.2 No.4, October 31, 2012

  ABSTRACT: Treatment-resistant schizophrenia has an extremely negative impact on mental health and social life. If clozapine, the gold standard treatment, fails, there are very few options left. The literature suggests that high-dose olanzapine (20 - 60 mg/day) is a possible alternative. We report two cases in which very high doses of olanzapine were administered, with significant clinical improvements above 60 mg/day. Clinical, metabolic and cardiac tolerance was good. This report highlights the usefulness of very-high-dose olanzapine in treatment-resistant schizophrenia. The main hypotheses concerning the psychopharmacological mechanisms of very-high-dose olanzapine are discussed.